Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.6352W HIGH $5.25
Volume
437.55 K
Value Traded
250.13 K
Short % Float
1.04%
-11.11%Week
-11.76%1 Month
+25%3 Month
+63.64%6 Month
-99.47%5 Year
-99.47%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
17.42 M
EPS (TTM)
-2.14
P/E Ratio
-
Ent. Value
17.01 M
Total Shares
4.80 M
Float Shares
3.85 M
Insiders
20.43%
Institutions
3.20%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
HSCS Catalyst Timeline
Dated clinical, regulatory and corporate events for HeartSciences Inc.
Past FDA Catalysts and PDUFA Decisions
How HSCS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
HeartSciences Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every HSCS program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Watson DanielleOfficer (See Remarks) | Grant/Award | 25,000 25,000 held | $0.00 | 07/07/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in HSCS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in HSCS for Q2 2026. | ||||
HSCS Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How HSCS ranks across every disease it competes in
Competitive Position is a premium feature
See how HSCS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialHSCS News
HSCS▼ -14.9%today
HeartSciences Receives FDA 510(k) Clearance for its MyoVista® wavECGTM Device
HeartSciences has received FDA 510(k) clearance for its MyoVista wav ECG device, allowing it to be used as a 12-lead resting electrocardiograph for both adult and pediatric patients. However, the clearance does not include an AI-ECG algorithm, which the company does not plan to commercialize without. The CEO expressed optimism about the clearance, viewing it as a valuable asset for future opportunities.
Read more →HSCSHeartSciences Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update
HeartSciences reported its fiscal first quarter 2027 results, highlighting progress on its proposed merger with Fortitude Mining Holdings, expected to close in Q4 2026. The company has signed its first commercial agreements for the MyoVista Insights platform and received positive feedback from clinicians. However, it reported no meaningful revenue and increased operational losses during the quarter.
Read more →HSCS▲ +19.5%on this news· ran to +30% by day 3
Fortitude Invests $1.0 Million in HeartSciences at a 22% Premium with No Adjustment to the Merger Consideration
Fortitude Mining Holdings has invested approximately $1 million in HeartSciences, purchasing shares at a 22% premium to the market price. This investment does not alter the merger agreement's exchange ratio, and Fortitude now owns about 9.4% of HeartSciences' shares. The funds will enhance HeartSciences' financial position ahead of its proposed merger with Fortitude, expected to close later this year.
Read more →HSCSHeartSciences Files Preliminary Proxy Statement for Business Combination with Fortitude Mining Holdings; Provides Business Update and Reports Fiscal 2026 Financial Results
HeartSciences has filed a preliminary proxy statement regarding its proposed business combination with Fortitude Mining Holdings, which is expected to create significant value for shareholders. The company reported its Fiscal 2026 results, highlighting the launch of the MyoVista Insights platform and the submission of its MyoVista wavECG device for FDA clearance. Despite facing challenges such as a lack of revenue and share price pressure, the partnership with Fortitude is viewed positively due to its strong position in the Zcash ecosystem.
Read more →HSCSHeartSciences Files Its Fiscal 2026 Annual Report on Form 10-K
HeartSciences Inc. has filed its Annual Report on Form 10-K for fiscal 2026 and plans to submit a preliminary proxy statement for a proposed merger with Fortitude Mining Holdings. The CEO highlighted fiscal 2026 as a landmark year with the launch of MyoVista Insights, which aims to enhance ECG technology. The merger is expected to create significant value for shareholders, although it is contingent on approval.
Read more →HSCS▲ +55.4%on this news· ran to +66% by day 3
Fortitude and HeartSciences (Nasdaq: HSCS) Announce Business Combination, Aiming to Bring a Leading Vertically-Integrated Zcash Mining Platform to the Public Markets
HeartSciences has announced a business combination aimed at launching a vertically-integrated Zcash mining platform in public markets. This initiative emphasizes privacy and aims to enhance the company's market presence. The move is expected to attract investor interest and expand operational capabilities.
Read more →HSCSEuropean Patent Granted for ECG-Based Assessment of Diastolic Function, Expands HeartSciences’ Patent Portfolio to More Than 45 Granted Patents
HeartSciences Inc. has been granted a European patent for its ECG-based assessment of diastolic function, enhancing its intellectual property portfolio to over 45 patents. This technology utilizes machine learning to estimate echocardiogram parameters from ECG data, potentially transforming cardiac disease assessment. The patent is effective in 19 European countries.
Read more →HSCSHeartSciences opens AI marketplace for heart care
HeartSciences has launched version 1.3 of its MyoVista Insights platform, introducing an AI-ECG Algorithm Marketplace. This platform allows healthcare providers to access FDA-cleared cardiac AI tools, enhancing the integration of AI into clinical workflows. The first algorithm from Bunkerhill Health aids in identifying reduced heart pumping function using routine ECGs. This initiative aims to simplify the adoption of AI in heart care and promote preventive healthcare.
Read more →HSCSHeartSciences Launches MyoVista Insights™ Version 1.3 with AI-ECG Algorithm Marketplace and First FDA-Cleared Algorithm
HeartSciences has launched MyoVista Insights version 1.3, featuring an AI-ECG Algorithm Marketplace that integrates third-party algorithms, starting with an FDA-cleared model from Bunkerhill Health. This platform aims to enhance clinical workflows and support earlier detection of heart failure. The company anticipates expanding the marketplace with more algorithms, positioning itself for significant revenue growth.
Read more →HSCSHeartSciences Signs Commercial Agreement with North Shore Health, the First Hospital Deployment from the Cibolo Health Network
HeartSciences has announced a commercial agreement with North Shore Health to deploy its MyoVista Insights platform, aimed at improving ECG management. This marks the first deployment within the Cibolo Health network, which has endorsed the platform. The agreement is expected to enhance workflow efficiency and support AI integration in clinical practices.
Read more →HSCS▲ +5.5%on this newsshared move
Welcome to the inaugural edition of The BEAT from HeartSciences.
HeartSciences has launched its inaugural newsletter, The BEAT, on May 11, 2026. This publication aims to provide timely insights and updates on advancements in cardiology, including technology trends and regulatory changes. The newsletter is designed to support healthcare leaders and clinicians in navigating the evolving landscape of cardiovascular care.
Read more →HSCSHeartSciences Signs First SaaS Revenues Agreement following full launch of MyoVista Insights™
HeartSciences Inc. has announced its first commercial revenue agreement with St. Vincent Health for the MyoVista Insights platform. This cloud-native, SaaS-based ECG management system aims to enhance clinical workflows and decision-making by integrating AI directly into routine procedures. The agreement signifies a major step for HeartSciences as it transitions into revenue-generating deployments, with expectations of securing additional contracts in the near future. The engagement with St. Vincent Health reflects the platform's potential to improve cardiac care.
Read more →HSCSHeartSciences Reminds Its Shareholders to Submit Their Vote at the Upcoming April 30, 2026, Annual Shareholders Meeting
HeartSciences Inc. is reminding shareholders to vote in the upcoming Annual Meeting on April 30, 2026. Shareholders can vote online before the deadline of April 29, 2026. The company emphasizes the importance of participation and provides resources for assistance. The meeting will be held virtually, allowing all eligible shareholders to engage.
Read more →HSCSHeartSciences’ MyoVista Insights™ Receives Epic Toolbox Designation for ECG Management System Category
HeartSciences has announced that its MyoVista Insights platform has received Epic Toolbox designation for the ECG Management System category. This designation signifies that MyoVista Insights meets Epic's recommended practices for integration, enhancing its usability within clinical workflows. The platform aims to improve workflow efficiency and support clinical decision-making through advanced AI integration.
Read more →HSCSHeartSciences to Present at Investor Summit Group Virtual Conference and Host Virtual One on One Investor Meetings
HeartSciences Inc. will present at the Investor Summit Group Virtual Conference on March 25, 2026. CEO Andrew Simpson is set to outline the company's business strategy and growth catalysts during the presentation. The event aims to enhance investor engagement and visibility in the capital markets, followed by one-on-one meetings with qualified investors.
Read more →HSCSHeartSciences Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
HeartSciences reported its fiscal third quarter 2026 results, highlighting advancements in its MyoVista Insights platform and the submission of the MyoVista wavECG device to the FDA for clearance. The company is focused on establishing reference sites and generating initial revenues, with positive feedback from early adopters. A significant upgrade to the platform was released ahead of the ACC Annual Scientific Session.
Read more →HSCSUniversity of West England Adopts HeartSciences’ MyoVista Insights™ Platform and MyoVista® wavECG™ Device to Establish ECG Education and Technology Reference Center
HeartSciences has partnered with the University of the West of England to implement its MyoVista Insights platform and MyoVista wavECG device for ECG education. This initiative aims to train future cardiac scientists and enhance the UK's cardiac diagnostic capabilities. The collaboration will also facilitate real-world validation of the technology in educational settings, supporting NHS workforce goals.
Read more →HSCSCibolo Health Designates HeartSciences’ MyoVista Insights™ as Endorsed ECG Management Platform for Network of 123 Independent Hospitals
HeartSciences has been designated by Cibolo Health as the endorsed ECG management platform for its network of 123 independent hospitals. This collaboration aims to modernize ECG workflows, improving efficiency and clinical decision-making. MyoVista Insights will provide secure, cloud-based ECG data management, integrating AI algorithms into routine practice. This partnership aligns with Cibolo Health's mission to enhance care delivery while managing costs.
Read more →HSCS▼ -6.5%on this news
HeartSciences Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
HeartSciences Inc. reported its fiscal second quarter 2026 financial results, highlighting progress in the commercialization of its MyoVista Insights healthcare IT platform. The company submitted its MyoVista wavECG device to the FDA for 510(k) premarket clearance, marking a significant regulatory milestone. Despite these advancements, HeartSciences reported no meaningful revenue for the quarter and has limited cash reserves.
Read more →HSCSHeartSciences Announces FDA 510(k) Submission for MyoVista® wavECG™ Device
HeartSciences has submitted its MyoVista wavECG device for FDA 510(k) clearance, aiming to enhance ECG functionality with AI integration. The decision to separate the submissions for the device and its AI-ECG software is intended to streamline the regulatory process. The company is also advancing its commercialization strategy and engaging in discussions with healthcare institutions.
Read more →About HeartSciences Inc.
Headquarters550 RESERVE ST, SUITE 360, SOUTHLAKE, TX, 76092
BIOPHARMAWATCH ELITE PLUS
Trade the next HSCS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime